Can probiotics supplementation improve glycemic & renal status in Diabetic Nephropathy? A systematic review and meta-analysis of clinical trials

Abstract

BACKGROUND & AIMS: This meta-analysis was performed to quantify the effects of probiotics on renal and glycemic biomarkers among patients with Diabetic Nephropathy (DN). METHODS: Electronic databases were searched through May 10, 2020. All trials that investigated the effect of probiotics on serum glycemic markers (Fasting Plasma Glucose FPG, Hemoglobin A1C, Insulin, Homeostatic Model AssessmentInsulin Resistance HOMA-IR, and Quantitative Insulin Sensitivity Check Index QUICKI), and renal status markers (Creatinine Cr, Blood Urea Nitrogen BUN, and Glomerular Filtration Rate GFR) were included. RESULTS: Seven trials that included 340 patients were identified for analysis. The results indicated that probiotics significantly reduced FPG (WMD= -19.08 mg/dl; 95% CI= -32.16, -5.99; P=0.004), HOMA-IR (WMD= -1.88; 95% CI= - 3.63, -0.12; P=0.036), and Cr (WMD= -0.18 mg/dl; 95% CI= -0.26, -0.09; P<0.001) levels in DN patients; however, there was no statistically significant change in Hemoglobin A1C, Insulin, QUICKI, BUN, and GFR. CONCLUSION: This meta-analysis supports the potential use of probiotics in the improvement of some glycemic and renal biomarkers in patients with DN.